基于新型肿瘤类器官的小鼠模型用于研究非侵入性精准内镜植入后直肠癌的图像引导放射治疗
研究建立了基于内镜精准注射肿瘤类器官的原位直肠癌小鼠模型,该模型可反映肿瘤异质性。采用内镜和计算机断层扫描引导放疗,并用小动物磁共振成像和内镜随访验证肿瘤生长及治疗反应。2次类器官注射后所有小鼠均成功形成直肠肿瘤,5×5 Gy临床相关放疗方案显著延迟肿瘤进展临床征象并显著改善生存。
要点
- 2次类器官注射后所有小鼠成功诱导直肠肿瘤形成。
- 5×5 Gy放疗显著延迟肿瘤进展临床征象并显著改善生存。
- 放疗后长期存活者经影像学分期和组织病理学检查未见肿瘤复发证据。
核心结论
- 新型小鼠模型结合了经非侵入性精准直肠类器官注射实现的原位肿瘤生长与小动物放疗。
- 该模型对研究肿瘤细胞内在因素、宿主遗传改变及外源性因素(如营养或微生物群)对放疗结局的影响具有重要前景。
- 该模型允许探索涉及化疗、免疫治疗或新型靶向治疗的联合疗法。
研究设计与样本
- 研究建立了基于精准定义的内镜注射肿瘤类器官的原位直肠癌小鼠模型,该模型反映肿瘤异质性。
- 采用内镜和计算机断层扫描引导放疗,并使用小动物磁共振成像和内镜随访验证直肠肿瘤生长及治疗反应率。
主要发现
- 2次类器官注射后所有小鼠均成功诱导直肠肿瘤形成。
- 临床相关放疗方案5×5 Gy显著延迟肿瘤进展临床征象并显著改善生存。
- 与人疾病一致,直肠肿瘤进展与肝和肺转移的发生相关。
- 放疗后长期存活者经体内放射学肿瘤分期和组织病理学检查显示无肿瘤复发证据。
关键数值与推荐
- 术前(新辅助)放疗是多模式直肠癌治疗的重要组成部分。
- 全程新辅助治疗(TNT)将同步放化疗与额外疗程化疗联合,在约30%的切除患者中达到病理完全缓解。
- 近期研究显示抗程序性细胞死亡蛋白1免疫治疗可在具有特定基因改变的患者中诱导临床完全缓解。
临床怎么用
- 原文未据此给出推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Preoperative (neoadjuvant) radiation therapy (RT) is an essential part of multimodal rectal cancer therapy. Recently, total neoadjuvant therapy (TNT), which combines simultaneous radiochemotherapy with additional courses of chemotherapy, has emerged as an effective approach. TNT achieves a pathologic complete remission in approximately 30% of resected patients, opening avenues for treatment strategies that avoid radical organ resection. Furthermore, recent studies have demonstrated that anti-programmed cell death protein 1 immunotherapy can induce clinical complete responses in patients with specific genetic alterations. There is significant potential to enhance outcomes through intensifying, personalizing, and de-escalating treatment approaches. However, the heterogeneous response rates to RT or TNT and strategies to sensitize patients without specific genetic changes to immunotherapy remain poorly understood. METHODS AND MATERIALS: We developed a novel orthotopic mouse model of rectal cancer based on precisely defined endoscopic injections of tumor organoids that reflect tumor heterogeneity. Subsequently, we employed endoscopic- and computed tomography-guided RT and validated rectal tumor growth and response rates to therapy using small-animal magnetic resonance imaging and endoscopic follow-up. RESULTS: Rectal tumor formation was successfully induced in all mice after 2 organoid injections. Clinically relevant RT regimens with 5 × 5 Gy significantly delayed clinical signs of tumor progression and significantly improved survival. Consistent with human disease, rectal tumor progression correlated with the development of liver and lung metastases. Notably, long-term survivors after RT showed no evidence of tumor recurrence, as demonstrated by in vivo radiologic tumor staging and histopathologic examination. CONCLUSIONS: Our novel mouse model combines orthotopic tumor growth via noninvasive and precise rectal organoid injection and small-animal RT. This model holds significant promise for investigating the effect of tumor cell-intrinsic aspects, genetic alterations of the host, and exogenous factors (eg, nutrition or microbiota) on RT outcomes. Furthermore, it allows for the exploration of combination therapies involving chemotherapy, immunotherapy, or novel targeted therapies.
引用
- Felchle H, Brunner V, Groll T, et al. Novel Tumor Organoid-Based Mouse Model to Study Image Guided Radiation Therapy of Rectal Cancer After Noninvasive and Precise Endoscopic Implantation. Int J Radiat Oncol Biol Phys. 2023. PMID: 37875245. doi:10.1016/j.ijrobp.2023.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。